Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InterMedical Care and Lab Hospital PCL (BKK:IMH-R) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
InterMedical Care and Lab Hospital PCL Capex-to-Revenue Related Terms
InterMedical Care and Lab Hospital PCL Capex-to-Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InterMedical Care and Lab Hospital PCL Capex-to-Revenue Chart
InterMedical Care and Lab Hospital PCL Annual Data
BKK:IMH-R vs HCA, THC, EHC: Capex-to-Revenue Comparison
For the Medical Care Facilities subindustry, InterMedical Care and Lab Hospital PCL's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InterMedical Care and Lab Hospital PCL Capex-to-Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, InterMedical Care and Lab Hospital PCL's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where InterMedical Care and Lab Hospital PCL's Capex-to-Revenue falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InterMedical Care and Lab Hospital PCL (BKK:IMH-R) has a Capex-to-Revenue of 0.01 as of Jun. 2026. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on InterMedical Care and Lab Hospital PCL and its competitors.
Is InterMedical Care and Lab Hospital PCL's Capex-to-Revenue too high?
InterMedical Care and Lab Hospital PCL's current Capex-to-Revenue is 0.01. Overall, InterMedical Care and Lab Hospital PCL has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InterMedical Care and Lab Hospital PCL's Capex-to-Revenue compare to HCA and THC?
InterMedical Care and Lab Hospital PCL's Capex-to-Revenue of 0.01 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Revenue for a Healthcare Providers & Services company?
A good Capex-to-Revenue depends on the Healthcare Providers & Services industry context. However, Capex-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Revenue mean?
A high Capex-to-Revenue can signal that a stock is expensive relative to its fundamentals. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on InterMedical Care and Lab Hospital PCL and its competitors. InterMedical Care and Lab Hospital PCL's current Capex-to-Revenue is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InterMedical Care and Lab Hospital PCL stock overvalued right now?
Based on GuruFocus' analysis, InterMedical Care and Lab Hospital PCL (BKK:IMH-R) is currently considered Possible Value Trap. The stock's GF Value™ is ฿5.85, compared to a current price of ฿3.62 — trading 38.1% below its estimated fair value. The current Capex-to-Revenue is 0.01. InterMedical Care and Lab Hospital PCL's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Revenue calculated?
Capex-to-Revenue is calculated from a company's financial statements. For InterMedical Care and Lab Hospital PCL (BKK:IMH-R), the current Capex-to-Revenue is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InterMedical Care and Lab Hospital PCL (BKK:IMH-R) Overvalued in 2026?
Based on GuruFocus' analysis, InterMedical Care and Lab Hospital PCL stock appears to be undervalued.
The current stock price of ฿3.62 is trading 38.1% below its estimated GF Value™ of ฿5.85.
GuruFocus considers InterMedical Care and Lab Hospital PCL to be Possible Value Trap.
Key valuation signals for BKK:IMH-R:
Capex-to-Revenue: 0.01
GF Value™: ฿5.85 vs. price of ฿3.62 (38.1% below fair value)
No single metric tells the full story. See the BKK:IMH-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InterMedical Care and Lab Hospital PCL is a company principally engaged in specialty medical hospitals, and occupational medicine. The business segments of the firm are Prachapat hospital, Occupational Medicine hospital and Environmental Analysis. Prachapat Hospital is engaged in rendering medical services to patients under government welfare schemes. Occupational Medicine Hospital is engaged in providing physical examination services. Majority of revenue is from Hospital Segment. Geographically, the company operates in Thailand.
70GF Score
Get the complete analysis for BKK:IMH-R
Capex-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:IMH-R has been successfully added to your 
